ARTICLE
14 February 2024

Distressed Asset Acquisition Opportunities For Biopharma Companies (Video)

AP
Arnold & Porter

Contributor

Arnold & Porter is a firm of more than 1,000 lawyers, providing sophisticated litigation and transactional capabilities, renowned regulatory experience and market-leading multidisciplinary practices in the life sciences and financial services industries. Our global reach, experience and deep knowledge allow us to work across geographic, cultural, technological and ideological borders.
A significant number of biopharmaceutical companies have recently filed for bankruptcy, often seeking to sell assets through the bankruptcy process, including via section 363 sales.
United States Insolvency/Bankruptcy/Re-Structuring
This article from Arnold & Porter is most popular:
  • within Insolvency/Bankruptcy/Re-Structuring topic(s)
Benjamin Mintz’s articles from Arnold & Porter are most popular:
  • within Insolvency/Bankruptcy/Re-Structuring topic(s)
Arnold & Porter are most popular:
  • within Insolvency/Bankruptcy/Re-Structuring and Environment topic(s)

A significant number of biopharmaceutical companies have recently filed for bankruptcy, often seeking to sell assets through the bankruptcy process, including via section 363 sales. Such bankruptcies can present significant opportunities for biopharma companies. Join Ben Mintz, Rosa Evergreen, and Eric Rothman, partners at Arnold & Porter, as they discuss the key features, timeline, process, and pros and cons of asset acquisitions in bankruptcy cases.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More